A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Elizabeth Henry
Loyola Univ. Medical Center
Principal Investigator - Fernando Quevedo, MD
Mayo Clinic
Principal Investigator - Jason Chesney, MD
Brown Cancer Center
Principal Investigator - Jhanelle Gray, MD
Moffitt Cancer Center
Principal Investigator - Laura Chow, MD
University of Washington
Principal Investigator - Lionel Lewis
Dartmouth-Hitchcock Medical Center
Principal Investigator - Martin Voss, MD
Memorial Sloan Kettering Cancer Center
Principal Investigator - Mohamad Salkeni, MD
Mary Babb Randolph Cancer Center
Principal Investigator - Monika Joshi, MD
Penn State Hershey Cancer Institute
Principal Investigator - Omid Hamid, MD
The Angeles Clinic
Principal Investigator - Peter Van Veldhuizen
Menorah Medical Center tour
Principal Investigator - Raid Aljumaily, MD
Peggy Charles Stephenson Cancer Center
Principal Investigator - Robert Alter, MD
John Theurer Cancer Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
27 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Research Site
East Bentleigh, Australia
- Research Site
Frankston, Australia
- Research Site
Toronto, Ontario, Canada
- Research Site
Montreal, Quebec, Canada
- Research Site
Bordeaux, France
- Research Site
Dijon, France
- Research Site
Marseille, France
- Research Site
Paris, France
- Research Site
Villejuif, France
- Research Site
Amsterdam, Netherlands
- Research Site
Groningen, Netherlands
- Research Site
Cambridge, United Kingdom
- Research Site
Cardiff, United Kingdom
- Research Site
Southampton, United Kingdom
- Research Site
Los Angeles, California, United States
- Research Site
Tampa, Florida, United States
- Research Site
Overland Park, Kansas, United States
- Research Site
Louisville, Kentucky, United States
- Research Site
Rochester, Minnesota, United States
- Research Site
Hackensack, New Jersey, United States
- Research Site
New York, New York, United States
- Research Site
Cleveland, Ohio, United States
- Research Site
Oklahoma City, Oklahoma, United States
- Research Site
Portland, Oregon, United States
- Research Site
Hershey, Pennsylvania, United States
- Research Site
Nashville, Tennessee, United States
- Research Site
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 19 May 2014
- Primary completion
- 17 Mar 2020
- Completion
- 17 Mar 2020
- Last update posted
- 1 Jun 2021
- Registered enrollment
- 97
- Registry id
- NCT02118337
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.